主页 > 医学新闻 >
【drug-news】研制效果更好、毒性更低抗肿瘤药物
Hope For A More Effective And Less Toxic Cancer Drug
Detailed evaluation conducted at WEHI into a possible new cancer drug suggests that it may prove to be more effective and less toxic than current chemotherapeutic drugs.
Dr David Huang, Dr Andrew Roberts, Prof Jerry Adams and their teams from WEHI's cancer research divisions have been assessing the potential of a new compound, ABT-737, that was developed by US-based healthcare company, Abbott.
Under normal circumstances, human cells have a limited lifespan. They die when they are damaged, worn out or no longer needed by the body. When they die, these cells are replaced by new ones. The body depends on a normal and healthy process called programmed cell death - or apoptosis - to ensure that unwanted cells die on cue. If this process fails, then the damaged cells live on and multiply indefinitely and uncontrollably. This uncontrolled multiplication of rogue cells can lead to cancer.
Conventional chemotherapeutic drugs target and attempt to kill rapidly dividing cancer cells. This is sometimes successful in halting the disease, but these drugs inevitably damage many normal tissues. Hence, even when the chemotherapy works, the side effects for the patient can be very serious.
ABT-737 is a drug with a different strategy for attacking cancer. Rather than attempting to poison the rogue cells, the new drug attempts to reactivate the healthy and normal cell death program that failed to kill the unwanted cells on cue.
WEHI's leading researcher with the assessment project, Dr David Huang, explains, "Normally, the cell death machinery is switched on when damaged cells need to be removed. The failure of the machinery to be turned on when it should can lead to cancer. ABT-737 is a 'switch flicker' that kicks the cell death machinery into action. Much more remains to be done to assess the drug's safety and effectiveness in patients, but early results from the laboratory are promising. Our hope is that the new drug will prove to be more effective while having fewer side effects."
The findings of the scientific assessment team are published in the 13 November 2006 issue of the prestigious international journal Cancer Cell. 认领!如48H后未交,请其他战友自由认领! Hope For A More Effective And Less Toxic Cancer Drug
研制更有效且低毒的癌症药物的希望
Detailed evaluation conducted at WEHI into a possible new cancer drug suggests that it may prove to be more effective and less toxic than current chemotherapeutic drugs.
由WEHI指导的关于一种可能的新肿瘤药物的详细评估,提示这种药物可能比现今的化疗药物更加有效且低毒.
Dr David Huang, Dr Andrew Roberts, Prof Jerry Adams and their teams from WEHI's cancer research divisions have been assessing the potential of a new compound, ABT-737, that was developed by US-based healthcare company, Abbott.
WEHI癌症研究部的David Huang博士, Andrew Roberts博士和Prof Jerry Adams 以及他们的研究小组已经对新化合物ABT-737进行了评估,这个新化合物是由基于医疗将康保健的公司Abbott研发的.
Under normal circumstances, human cells have a limited lifespan. They die when they are damaged, worn out or no longer needed by the body. When they die, these cells are replaced by new ones. The body depends on a normal and healthy process called programmed cell death - or apoptosis - to ensure that unwanted cells die on cue. If this process fails, then the damaged cells live on and multiply indefinitely and uncontrollably. This uncontrolled multiplication of rogue cells can lead to cancer.
在正常情况下,人类细胞有一个有限的生命周期,当细胞受到损伤,破损或者不再被机体所需要时,他们就会死亡,并且被新的细胞所代替.机体依赖于一个正常健全的被称作是细胞程序性死亡或凋亡的机制,以确保那些不需要的细胞在预定的时间死亡.如果这个程序不能顺利执行,那么受损的细胞就会继续存在并不确定的进行复制且失去控制.这种'缺陷"细胞失去控制的复制能够导致癌症.
Conventional chemotherapeutic drugs target and attempt to kill rapidly dividing cancer cells. This is sometimes successful in halting the disease, but these drugs inevitably damage many normal tissues. Hence, even when the chemotherapy works, the side effects for the patient can be very serious.
常规的化疗药物针对且试图杀死那些迅速分裂的癌症细胞,这在有些时候是有效的治疗策略(是否应把这句翻译成:有时候这种治疗策略是否成功是不确定的),但是这些药物也不可避免的损伤了很多正常组织.因此,尽管化疗药物在起作用,但对于患者来说那些副作用也很严重.
ABT-737 is a drug with a different strategy for attacking cancer. Rather than attempting to poison the rogue cells, the new drug attempts to reactivate the healthy and normal cell death program that failed to kill the unwanted cells on cue.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-03 17:11
医学,生命科学网